Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 121NIH 15INDUSTRY 3OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

Dexamethasone 4Cyclophosphamide 4pomalidomide 2pegylated granulocyte colony-stimulating factor 2pegfilgrastim 2fludarabine 2carfilzomib 2Etoposide 2Cytarabine 2Bortezomib 2fosaprepitant 1fludarabine phosphate 1daratumumab 1Zoledronic Acid 1Vaccination 1Tropisetron 1Thiotepa 1Renal Replacement Therapy 1Prednisone 1Pneumococcal Vaccines 1Olanzapine 1Melphalan 1Lenalidomide 1Granulocyte Colony-Stimulating Factor 1Cyclosporine 1Azacitidine 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × fludarabine phosphate × Plasma cell × Clear all
NCT05528887 2022-09-06

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

The Affiliated People's Hospital of Ningbo University

Phase 1 Recruiting
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡